The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
Open accessAbstract
Attaching a cytotoxic "payload" to an antibody to form an antibody-drug conjugate (ADC) provides a mechanism for selective delivery of the cytotoxic agent to cancer cells via the specific binding of the antibody to cancer-selective cell surface molecules. The first ADC to receive marketing authorization was gemtuzumab ozogamicin, which comprises an anti-CD33 antibody conjugated to a highly potent DNA-targeting antibiotic, calicheamicin, approved in 2000 for treating acute myeloid leukemia. It was withdrawn from the US market in 2010 following an unsuccessful confirmatory trial. The development of two classes of highly potent microtubule-disrupting agents, maytansinoids and auristatins, as payloads for ADCs resulted in approval of brentuximab vedotin in 2011 for treating Hodgkin lymphoma and anaplastic large cell lymphoma, and approval of ado-trastuzumab emtansine in 2013 for treating HER2-positive breast cancer. Their success stimulated much research into the ADC approach, with >60 ADCs currently in clinical evaluation, mostly targeting solid tumors. Five ADCs have advanced into pivotal clinical trials for treating various solid tumors-platinum-resistant ovarian cancer, mesothelioma, triple-negative breast cancer, glioblastoma, and small cell lung cancer. The level of target expression is a key parameter in predicting the likelihood of patient benefit for all these ADCs, as well as for the approved compound, ado-trastuzumab emtansine. The development of a patient selection strategy linked to target expression on the tumor is thus critically important for identifying the population appropriate for receiving treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They bind to cell surface receptors that are upregulated by mutant RAS and exhibit potent antitumor activity, demonstrating their efficacy in targeting undruggable proteins outside the cell.645–649”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [646]
In the citing paper
“They bind to cell surface receptors that are upregulated by mutant RAS and exhibit potent antitumor activity, demonstrating their efficacy in targeting undruggable proteins outside the cell.645–649”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [646]
In the citing paper
“They bind to cell surface receptors that are upregulated by mutant RAS and exhibit potent antitumor activity, demonstrating their efficacy in targeting undruggable proteins outside the cell.645–649”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [646]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
Köhler, G., & Milstein, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,200
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Govindan, R., Page, N. C., Morgensztern, D., Read, W. L., Tierney, R. M., Vlahiotis, A., Spitznagel, E. L., & Piccirillo, J. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4859 · Cited by 1,844
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Hidalgo, M. M., Amant, F. C., Biankin, A. V., Budínská, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Mælandsmo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0001 · Cited by 1,797
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Phillips, G. D. L., Li, G., Dugger, D. L., Crocker, L., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,708
Self-citationYounes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,528
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O'Brien, S. M., Wang, K., Wang, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509277 · Cited by 1,444
Polymer Therapeutics: Concepts and Applications
Haag, R., & Kratz, F. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200502113 · Cited by 1,119
Pro, B., Advani, R. H., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M. A., Connors, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0402 · Cited by 1,004
Research works printed but not linked: 1
- Hassan R, Bendell JC, Blumenschein Jr G, Kindler HL, Moore KN, Santin AD, Seward SM, Nemunaitis J, Rajagopalan P, Walter A, Sarapa N. Phase I study of anti-mesothelin antibody-drug conjugate anetumab ravtansine (BAY 94-9394). 16th World Conference on Lung Cancer, Denver CO. 2015; presentation No. 1574.
Cited by
Sorted by citations
Scinto, S. L., Bilodeau, D. A., Hincapie, R., Lee, W., Nguyen, S. S., Xu, M., Ende, C. W. A., Finn, M. G., Lang, K., Lin, Q., et al. (2021) · Nature Reviews Methods Primers · doi:10.1038/s43586-021-00028-z · Cited by 654
Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Staudacher, A. H., & Brown, M. P. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.367 · Cited by 561
Antibody-Drug Conjugate-Based Therapeutics: State of the Science
Birrer, M. J., Moore, K. N., Betella, I., & Bates, R. C. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz035 · Cited by 456
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Antibody–Drug Conjugates: The Last Decade
Joubert, N., Beck, A., Dumontet, C., & Denevault‐Sabourin, C. (2020) · Pharmaceuticals · doi:10.3390/ph13090245 · Cited by 380
Antibody–Drug Conjugates for Cancer Treatment
Lambert, J. M., & Berkenblit, A. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-061516-121357 · Cited by 315
Self-citationPotential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
Mahalingaiah, P. K., Ciurlionis, R., Durbin, K. R., Yeager, R. L., Philip, B. K., Bawa, B., Mantena, S. R., Enright, B. P., Liguori, M. J., & Van Vleet, T. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.008 · Cited by 286
Causes, consequences, and therapy of tumors acidosis
Pillai, S., Damaghi, M., Marunaka, Y., Spugnini, E. P., Fais, S., & Gillies, R. J. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09792-7 · Cited by 286
Rossin, R., Versteegen, R. M., Wu, J., Khasanov, A. B., Wessels, H. J. C. T., Steenbergen, E. J., ten Hoeve, W., Janssen, H. M., van Onzen, A. H. A. M., Hudson, P. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03880-y · Cited by 280
Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes
Abdollahpour‐Alitappeh, M., Lotfinia, M., Gharibi, T., Mardaneh, J., Farhadihosseinabadi, B., Larki, P., Faghfourian, B., Sepehr, K. S., Abbaszadeh‐Goudarzi, K., Abbaszadeh‐Goudarzi, G., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27419 · Cited by 257
LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
Purcell, J. W., Tanlimco, S. G., Hickson, J. A., Fox, M., Sho, M., Durkin, L. M., Uziel, T., Powers, R., Foster, K., McGonigal, T. P., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0327 · Cited by 213
Mechanisms of Therapeutic Antitumor Monoclonal Antibodies
Tsao, L.-C., Force, J. M., & Hartman, Z. C. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1109 · Cited by 215
A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy
Riccardi, F., Bo, M. D., Macor, P., & Toffoli, G. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1274088 · Cited by 207
EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles
Santos, E. D. S., Nogueira, K. A. B., Crisóstomo, L. C. C. F., Martins, J. R. P., Reis, A. V. F., Neto, J. D. B. V., da Silva, I. J., Pessoa, C., Petrilli, R., & Eloy, J. O. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.120082 · Cited by 194
Chemotherapeutic agents for the treatment of metastatic breast cancer: An update
Abotaleb, M., Kubatka, P., Čaprnda, M., Varghese, E., Zolakova, B., Žúbor, P., Opatřilová, R., Kružliak, P., Štefanička, P., & Büsselberg, D. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.108 · Cited by 193
Mitochondrial-Targeting Anticancer Agent Conjugates and Nanocarrier Systems for Cancer Treatment
Battogtokh, G., Cho, Y., Lee, J. Y., Lee, H. S., & Kang, H. C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00922 · Cited by 179
Antibody therapeutics and immunoregulation in cancer and autoimmune disease
Yasunaga, M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.001 · Cited by 168
Advances and Limitations of Antibody Drug Conjugates for Cancer
Mckertish, C. M., & Kayser, V. (2021) · Biomedicines · doi:10.3390/biomedicines9080872 · Cited by 172
Trail, P. A., Dubowchik, G. M., & Lowinger, T. B. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.013 · Cited by 141
Challenges and new frontiers in analytical characterization of antibody-drug conjugates
Wagh, A. V., Song, H., Zeng, M., Tao, L., & Das, T. K. (2018) · mAbs · doi:10.1080/19420862.2017.1412025 · Cited by 136
Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
Zhang, M., Liu, E., Cui, Y., & Huang, Y. (2017) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2017.0054 · Cited by 134
Hammood, M., Craig, A. W., & Leyton, J. V. (2021) · Pharmaceuticals · doi:10.3390/ph14070674 · Cited by 140
Current status and contemporary approaches to the discovery of antitumor agents from higher plants
Agarwal, G., Carcache, P. J. B., Addo, E. M., & Kinghorn, A. D. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.01.004 · Cited by 116
MMAE Delivery Using the Bicycle Toxin Conjugate BT5528
Bennett, G. S., Brown, A. N., Mudd, G., Huxley, P., Rietschoten, K. V., Pavan, S., Chen, L., Watcham, S. M., Lahdenranta, J., & Keen, N. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1092 · Cited by 105
A Review of Mirvetuximab Soravtansine in the Treatment of Platinum-Resistant Ovarian Cancer
Moore, K. N., Martin, L. P., O’Malley, D. M., Matulonis, U. A., Konner, J. A., Vergote, I. B., Ponte, J. F., & Birrer, M. J. (2017) · Future Oncology · doi:10.2217/fon-2017-0379 · Cited by 102
Drug conjugate-based anticancer therapy - Current status and perspectives
Yang, Y., Wang, S., Ma, P., Jiang, Y., Cheng, K., Yu, Y., Jiang, N., Miao, H., Tang, Q., Liu, F., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215969 · Cited by 101
Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges
Wang, M., Yu, F., & Zhang, Y. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02214-5 · Cited by 110
Sifniotis, V., Cruz, E., Eroglu, B., & Kayser, V. (2019) · Antibodies · doi:10.3390/antib8020036 · Cited by 99
Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?
Deonarain, M. P., Yahioglu, G., Stamati, I., Pomowski, A., Clarke, J., Edwards, B. M., Diez-Posada, S., & Stewart, A. (2018) · Antibodies · doi:10.3390/antib7020016 · Cited by 94
Photosensitizer Antibody–Drug Conjugates: Past, Present, and Future
Sandland, J., & Boyle, R. W. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00055 · Cited by 92
Larionov, A. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00089 · Cited by 95
Demetri, G. D., Luke, J. J., Hollebecque, A., Powderly, J. D., Spira, A. I., Subbiah, V., Naumovski, L., Chen, C., Fang, H. A., Lai, D. W., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4513 · Cited by 88
Chomet, M., van Dongen, G. A. M. S., & Vugts, D. J. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00136 · Cited by 88
King, G. T., Eaton, K. D., Beagle, B. R., Zopf, C. J., Wong, G. Y., Krupka, H. I., Hua, S. Y., Messersmith, W. A., & El-Khoueiry, A. B. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0560-6 · Cited by 87
Current status of nanomedicine in the chemotherapy of breast cancer
Fraguas‐Sánchez, A. I., Martín‐Sabroso, C., Fernández-Carballido, A. M., & Torres‐Suárez, A. I. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03910-6 · Cited by 86
Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy
Dubuisson, A., & Micheau, O. (2017) · Antibodies · doi:10.3390/antib6040016 · Cited by 81
Kim, S., Meric‐Bernstam, F., Kalyan, A., Babich, A., Liu, R., Tanigawa, T., Sommer, A., Osada, M., Reetz, F., Laurent, D., et al. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00670-4 · Cited by 77
Moore, K. N., Vergote, I. B., Oaknin, A., Colombo, N., Banerjee, S. N., Oza, A. M., Pautier, P., Malek, K. S., & Birrer, M. J. (2018) · Future Oncology · doi:10.2217/fon-2017-0646 · Cited by 79
HER2 expression in urothelial carcinoma, a systematic literature review
Scherrer, E., Kang, A., Bloudek, L. M., & Koshkin, V. S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1011885 · Cited by 76
Zhu, G., Foletti, D. L., Liu, X., Ding, S., Witt, J. M., Hasa-Moreno, A., Rickert, M., Holz, C., Aschenbrenner, L. M., Yang, A. H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-44874-0 · Cited by 73
Nanoparticles-mediated CRISPR/Cas9 delivery: Recent advances in cancer treatment
Aghamiri, S., Talaei, S., Ghavidel, A. A., Zandsalimi, F., Masoumi, S., Hafshejani, N. H., & Jajarmi, V. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101533 · Cited by 70
Perrone, E., Lopez, S., Zeybek, B., Bellone, S., Bonazzoli, E., Pelligra, S., Zammataro, L. A., Manzano, A., Manara, P., Bianchi, A., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00118 · Cited by 68
Site-Specific Conjugation of Native Antibodies Using Engineered Microbial Transglutaminases
Dickgießer, S., Rieker, M., Müller-Pompalla, D., Schröter, C. J., Tonillo, J., Warszawski, S., Raab-Westphal, S., Kühn, S. F., Knehans, T., Könning, D., et al. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00061 · Cited by 65
Liu, H., Sun, M., Liu, Z., Kong, C., Kong, W., Ye, J., Gong, J., Huang, D. C. S., & Qian, F. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.014 · Cited by 67
Bi-specific tenascin-C and fibronectin targeted peptide for solid tumor delivery
Lingasamy, P., Tobi, A., Haugas, M., Hunt, H., Paiste, P., Asser, T., Rätsep, T., Kotamraju, V. R., Bjerkvig, R., & Teesalu, T. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119373 · Cited by 65
Clinical Pharmacology of Antibody-Drug Conjugates
Mahmood, I. (2021) · Antibodies · doi:10.3390/antib10020020 · Cited by 63
Huang, L., Wang, R., Xie, K., Zhang, J., Tao, F., Pi, C., Feng, Y., Gu, H., & Fang, J. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06384-4 · Cited by 63
PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer
Sau, S., Petrovici, A., Alsaab, H. O., Bhise, K., & Iyer, A. K. (2019) · Cancers · doi:10.3390/cancers11020232 · Cited by 63
Recent progress in transglutaminase-mediated assembly of antibody-drug conjugates
Schneider, H., Deweid, L., Avrutina, O., & Kolmar, H. (2020) · Analytical Biochemistry · doi:10.1016/j.ab.2020.113615 · Cited by 61
The BAFF-APRIL System in Cancer
Ullah, M. A., & Mackay, F. (2023) · Cancers · doi:10.3390/cancers15061791 · Cited by 60
Rottey, S., Clarke, J., Aung, K. L., Machiels, J.-P., Markman, B., Heinhuis, K. M., Millward, M., Lolkema, M. P., Patel, S. P., de Souza, P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1181 · Cited by 61
Antibody-Drug Conjugates: A promising breakthrough in cancer therapy
Parit, S., Manchare, A., Gholap, A. D., Mundhe, P., Hatvate, N. T., Rojekar, S. V., & Patravale, V. B. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124211 · Cited by 59
Li, W., Guo, H., Li, L., Zhang, Y., & Cui, J. (2021) · Cancer Medicine · doi:10.1002/cam4.4052 · Cited by 59
Yue, W., Wu, S., Liu, Z., Niu, J., Zhou, Y., Ren, J., & Qu, X. (2022) · Materials Today · doi:10.1016/j.mattod.2022.01.024 · Cited by 57
Exploiting LRRC15 as a Novel Therapeutic Target in Cancer
Ray, U., Pathoulas, C. L., Thirusangu, P., Purcell, J. W., Kannan, N., & Shridhar, V. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3734 · Cited by 56
Recent advances of nanomedicines for liver cancer therapy
Chi, X., Liu, K., Luo, X., Yin, Z., Lin, H., & Gao, J. (2020) · Journal of Materials Chemistry B · doi:10.1039/c9tb02871d · Cited by 57
Enzyme-Based Labeling Strategies for Antibody–Drug Conjugates and Antibody Mimetics
Falck, G., & Müller, K. M. (2018) · Antibodies · doi:10.3390/antib7010004 · Cited by 58
Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001
Abrahams, C. L., Li, X., Embry, M. G., Yu, A., Krimm, S., Krueger, S. A., Greenland, N., Wen, K. W., Jones, C., DeAlmeida, V. I., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26491 · Cited by 55
Sharma, S., Li, Z., Bussing, D., & Shah, D. K. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.089276 · Cited by 54
Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody–Drug Conjugates
Neumann, C. S., Olivas, K. C., Anderson, M. E., Cochran, J. H., Jin, S., Li, F., Loftus, L. V., Meyer, D. W., Neale, J. R., Nix, J. C., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0643 · Cited by 51
Bodyak, N. D., Mosher, R. E., Yurkovetskiy, A. V., Yin, M., Bu, C., Conlon, P. R., Demady, D. R., DeVit, M. J., Gumerov, D. R., Gurijala, V. R., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0183 · Cited by 50
Yang, J., & Bae, H. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01080-3 · Cited by 51
Jain, K. K. (2020) · Medical Principles and Practice · doi:10.1159/000511107 · Cited by 53
Satomaa, T., Pynnönen, H., Vilkman, A., Kotiranta, T., Pitkänen, V., Heiskanen, A., Herpers, B., Price, L., Helin, J., & Saarinen, J. (2018) · Antibodies · doi:10.3390/antib7020015 · Cited by 47
Seyyednia, E., Oroojalian, F., Baradaran, B., Mojarrad, J. S., Mokhtarzadeh, A., & Valizadeh, H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.044 · Cited by 47
Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?
Parakh, S., Nicolazzo, J. A., Scott, A. M., & Gan, H. K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.718590 · Cited by 46
Li, L., Zhu, Y., Liu, M., Jin, D., Zhang, L., Cheng, J., & Liu, Y. (2021) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2021.111553 · Cited by 45
Humanized anti-Sialyl-Tn antibodies for the treatment of ovarian carcinoma
Eavarone, D. A., Al-Alem, L., Lugovskoy, A. A., Prendergast, J. M., Nazer, R. I., Stein, J. N., Dransfield, D. T., Behrens, J., & Rueda, B. R. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201314 · Cited by 45
Kollmannsberger, C., Choueiri, T. K., Heng, D. Y. C., George, S., Jie, F., Croitoru, R., Poondru, S., & Thompson, J. A. (2020) · The Oncologist · doi:10.1002/onco.13628 · Cited by 45
Targeting the Microenvironment for Treating Multiple Myeloma
Neumeister, P., Schulz, E., Pansy, K., Szmyra, M., & Deutsch, A. J. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147627 · Cited by 43
Petrilli, R., Pinheiro, D. P., de Oliveira, F. D. C. E., Galvão, G. F., Marques, L. G. A., Lopez, R. F. V., Pessoa, C., & Eloy, J. O. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200525161359 · Cited by 45
Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides
Simón‐Gracia, L., Hunt, H., & Teesalu, T. (2018) · Molecules · doi:10.3390/molecules23051190 · Cited by 44
Theunissen, J.-W. F., Cai, A. G., Bhatti, M. M., Cooper, A. B., Avery, A. D., Dorfman, R., Guelman, S. A., Levashova, Z. B., & Migone, T. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0471 · Cited by 44
Skrzypczak, N., & Przybylski, P. (2022) · Natural Product Reports · doi:10.1039/d2np00004k · Cited by 43
Luginbuehl, V., Meier, N., Kovar, K., & Rohrer, J. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.02.005 · Cited by 40
Therapeutic antibodies: A new era in the treatment of respiratory diseases?
Sécher, T., Guilleminault, L., Reckamp, K. L., Amanam, I. U., Plantier, L., & Heuzé‐Vourc'h, N. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.003 · Cited by 42
Quantitative collision‐induced unfolding differentiates model antibody–drug conjugates
Tian, Y., Lippens, J. L., Netirojjanakul, C., Campuzano, I. D. G., & Ruotolo, B. T. (2018) · Protein Science · doi:10.1002/pro.3560 · Cited by 40
Tiwari, R., Shinde, P. S., Sreedharan, S., Dey, A. K., Vallis, K. A., Mhaske, S. B., Pramanik, S. K., & Das, A. (2020) · Chemical Science · doi:10.1039/d0sc06270g · Cited by 40
Homing Peptides for Cancer Therapy
Lingasamy, P., & Teesalu, T. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-58174-9_2 · Cited by 42
Lucas, A. T., Moody, A., Schorzman, A. N., & Zamboni, W. C. (2021) · Antibodies · doi:10.3390/antib10030030 · Cited by 40
Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate
Singh, S., Serwer, L., DuPage, A., Elkins, K., Chauhan, N., Ravn, M., Buchanan, F., Wang, L., Krimm, M., Wong, K., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0193 · Cited by 41
Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
González-Ochoa, E., Veneziani, A. C., & Oza, A. M. (2023) · Clinical Medicine Insights Oncology · doi:10.1177/11795549231187264 · Cited by 41
Zhang, C., Ötjengerdes, R., Roewe, J., Mejı́as, R., & Marschall, A. L. J. (2020) · BioDrugs · doi:10.1007/s40259-020-00419-w · Cited by 44
Puerto‐Camacho, P., Amaral, A. T., Lamhamedi-Cherradi, S.-E., Menegaz, B. A., Castillo‐Ecija, H., Ordóñez, J. L., Domínguez-Hormaetxe, S., Jordán-Pérez, C., Díaz‐Martín, J., Romero‐Pérez, L., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0936 · Cited by 38
Chomet, M., Schreurs, M., Nguyen, M. T. L., Howng, B., Villanueva, R., Krimm, M., Vasiljeva, O. S., van Dongen, G. A. M. S., & Vugts, D. J. (2020) · Theranostics · doi:10.7150/thno.44334 · Cited by 39
Mao, K., Chen, P., Sun, H., Zhong, S., Zheng, H., & Xu, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1425617 · Cited by 38
Antibody-Drug Conjugates in Bladder Cancer
Vlachostergios, P. J., Jakubowski, C. D., Niaz, M. J., Lee, A., Thomas, C., Hackett, A. L., Patel, P. H., Rashid, N., & Tagawa, S. T. (2018) · Bladder Cancer · doi:10.3233/blc-180169 · Cited by 38
Tsujii, S., Serada, S., Fujimoto, M., Uemura, S., Namikawa, T., Nomura, T., Murakami, I., Hanazaki, K., & Naka, T. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0335 · Cited by 37
Gregson, S. J., Masterson, L. A., Wei, B. Q., Pillow, T. H., Spencer, S. D., Kang, G., Yu, S., Raab, H. E., Lau, J., Li, G., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00736 · Cited by 37
Garofalo, M., Grazioso, G., Cavalli, A., & Sgrignani, J. (2020) · Molecules · doi:10.3390/molecules25071756 · Cited by 39
Shin, S. H., Park, Y., Park, S. S., Ju, E. J., Park, J. H., Ko, E. J., Bae, D. J., Kim, S., Chung, C., Song, H. Y., et al. (2021) · Advanced Science · doi:10.1002/advs.202102414 · Cited by 35
Novel immunotherapeutic approaches for hepatocellular carcinoma treatment
Busato, D., Mossenta, M., Baboçi, L., Cintio, F. D., Toffoli, G., & Bo, M. D. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1598859 · Cited by 36
Wang, X., Shirke, A. A., Walker, E., Sun, R., Ramamurthy, G., Wang, J., Shan, L., Mangadlao, J. D., Dong, Z., Li, J., et al. (2021) · Cancers · doi:10.3390/cancers13030417 · Cited by 34
Snyder, J., Malinao, M.-C., Dugal‐Tessier, J., Atkinson, J. E., Anand, B. S., Okada, A., & Mendelsohn, B. A. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00225 · Cited by 34
Characterization of Ring-Opening Reaction of Succinimide Linkers in ADCs
Zheng, K., Chen, Y., Wang, J. C. K., Zheng, L. Y., Hutchinson, M. H., Persson, J., & Ji, J. A. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.10.063 · Cited by 33
Tackling solid tumour therapy with small-format drug conjugates
Deonarain, M. P., & Xue, Q. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa024 · Cited by 33
Zhang, C., Han, M., Zhang, F., Yang, X., Du, J., Zhang, H., Li, W., & Chen, S. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s231144 · Cited by 32
Xu, T., Ding, H., Vorobyeva, A., Oroujeni, M., Orlova, A., Максимилианович, Т. В., & Gräslund, T. (2020) · Cancers · doi:10.3390/cancers13010085 · Cited by 32
A “Dual” Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC
Singh, A. P., & Shah, D. K. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.01.034 · Cited by 31
Schneider, H., Deweid, L., Pirzer, T., Yanakieva, D., Englert, S., Becker, B., Avrutina, O., & Kolmar, H. (2019) · ChemistryOpen · doi:10.1002/open.201900066 · Cited by 31
Metadata
- Authors
- Lambert, J. M., & Morris, C. Q.
- Affiliations
- ImmunoGen (United States) (US)
- Corresponding author
- Lambert, John M.
- Venue
- Advances in Therapy
- Published
- 2017-03-30
- Volume
- 34
- Issue
- 5
- Pages
- 1015-1035
- ISSN
- 0741-238X (ISSN-L)
- 1865-8652
- PMC
- PMC5427099
- OpenAlex
- W2603088210
- Cited by
- 304
- References
- 102
- Citations by year
- 2026: 30 · 2025: 21 · 2024: 18 · 2023: 24 · 2022: 16 · 2021: 49 · 2020: 48 · 2019: 45 · 2018: 45 · 2017: 7
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Advances in Therapy (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- antibody-drug conjugates, solid tumors, precision oncology, targeted drug delivery, maytansinoids, auristatin, calicheamicin, gemtuzumab ozogamicin, brentuximab vedotin, trastuzumab emtansine, target expression, patient selection, platinum-resistant ovarian cancer, mesothelioma, triple-negative breast cancer, glioblastoma, small cell lung cancer, cytotoxic payloads
- MeSH terms
- Trastuzumab, Gemtuzumab, Ado-Trastuzumab Emtansine, Aminoglycosides, Antineoplastic Agents, Humans, Maytansine, Neoplasms, Oligopeptides, Immunoconjugates, Antibodies, Monoclonal, Humanized, Aminobenzoates, Sialic Acid Binding Ig-like Lectin 3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
